Fierce Biotech September 11, 2024
Roche is holding out hopes that its injectable obesity prospect could eventually demonstrate 25% weight loss in late-stage trials, the pharma’s head of metabolism R&D has told Fierce Biotech.
The Swiss Big Pharma imported a pipeline of three molecules as part of its $2.7 billion acquisition of Carmot Therapeutics at the end of last year, including an injectable dual GLP-1/GIP receptor agonist dubbed CT-388.
The candidate has already demonstrated average placebo-adjusted weight loss of 18.8% over 24 weeks in a phase 1b study, and Roche is using the European Association for the Study of Diabetes Annual Meeting in Madrid, Spain this week to take a deeper dive into the data.
Talking to Fierce from the sidelines of the conference, Manu...
Today's Sponsors
Today's Sponsor